President And Chief Executive Officer, GeneDX

Katherine Stueland joined GeneDx in June of 2021 as the President and CEO. Katherine is passionate about how genomics can improve health outcomes and is committed to ensuring GeneDx delivers industry-leading genetic and genomic testing to anyone who could benefit. With a relentless focus on putting patients at the center of business strategies, Katherine cares deeply about the importance of broadening research to diverse patient populations to advance science and patient care for everyone.

Previously, Katherine led Invitae’s (NYSE:NVTA) global commercial teams, including sales, international, biopharma partnerships, the direct ordering channel for patients, marketing, customer service, new market development, and communications/investor relations. In a previous role, she led Invitae’s communications and investor relations team and led the process to take the company from private to public. Prior to joining Invitae, Katherine worked with management teams of biopharma companies, including serving as Vice President of Communications and Investor Relations at Dendreon, the first company to bring an immuno-oncology product to market. Katherine holds a B.S. in English Language and Literature from Miami University in Ohio.